Effect of pentoxifylline in reducing proteinuria in patients with type 2 of diabetes

Effect of pentoxifylline as an intervention to reduce proteinuria in patients with type 2 of diabetes treated with angiotensin system blockers compared with patients (control group) were treated with ACEI or ARB

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016111827097N2

Enrollment

Registered

2016-12-01

Start date

2016-11-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabete. Diabetic nephropathy

Interventions

Intervention 1: Case group: Pentoxifylline, Tablet 400mg oral BD for 2 month Losartan, Tablet 50mg oral OD for 2 month Captopril, Tablet 50mg oral BD for 2 month. Intervention 2: Control group: Losart

Treatment - Drugs

Case group: Pentoxifylline, Tablet 400mg oral BD for 2 month Losartan, Tablet 50mg oral OD for 2 month Captopril, Tablet 50mg oral BD for 2 month

Control group: Losartan, Tablet 50mg oral OD for 2 month Captopril, Tablet 50mg oral BD for 2 month

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with type 2 of diabetes; proteinuria greater than 500 mg per 24 hours; people who are treated with ACEI and ARB; patients who do not have contra-indications of PTX. Exclusion criteria: proteinuria less than 500 mg per 24 hours; people who had a history of retinal hemorrhages; who had a history of MI; patients who have contra-indications of PTX; those treated with ACEI and ARB not; people who have hypotension

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Proteinuria. Timepoint: befor and after the study. Method of measurement: mg/d.	—

Secondary

Measure	Time frame
Urea. Timepoint: befor and after the study. Method of measurement: mg/dl.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Shadab Mirfakhrayi

Ardebil University of Medical Sciences

shadabmirfakhrayi@icloud.com+98 45 3351 2006

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026